Integrase inhibitor

DRUG3 trials

Sponsors

Hoffmann-La Roche, McGill University Health Centre/Research Institute of the McGill University Health Centre, Instituto Mexicano del Seguro Social

Conditions

HIVHIV Associate Weight LossHIV InfectionsHIV-1 InfectionIntegrase Inhibitors, HIV; HIV PROTEASE INHIBWeight ChangeWeight Loss

Phase 4

A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients

TerminatedNCT00488059

Hoffmann-La RocheHIV Infections

Start: 2007-06-30End: 2008-10-31Updated: 2011-07-22

Protease Inhibitor Vs. Raltegravir-based ART and Inflammation in HIV Infection

CompletedNCT02691065

McGill University Health Centre/Research Institute of the McGill University Health CentreHIV

Start: 2017-01-20End: 2021-03-31Updated: 2024-11-20

Change in Body Weight and BMI in PWH with DOR/3TC/TDF Compared with INSTI

RecruitingNCT06602622

Instituto Mexicano del Seguro SocialHIV, HIV-1 Infection, HIV Associate Weight Loss +3

Start: 2024-08-14End: 2025-11-14Target: 108Updated: 2024-09-19